Ukoniq (umbralisib) vs Columvi (glofitamab-gxbm)

Ukoniq (umbralisib) is a small molecule inhibitor specifically designed to target and inhibit PI3K delta and CK1 epsilon, making it suitable for the treatment of certain types of lymphomas and leukemias, such as marginal zone lymphoma (MZL) and follicular lymphoma (FL). On the other hand, Glofitamab (previously known as Columvi, with the proposed INN of glofitamab-gxbm) is a bispecific monoclonal antibody designed to engage both CD20 on B-cells and CD3 on T-cells, thereby redirecting T-cells to kill B-cells, and is being investigated as a treatment for B-cell non-Hodgkin lymphomas. The choice between these two medications would depend on the specific type of blood cancer a patient has, their previous treatments, and how they've responded, as well as the safety profile and mode of administration of the drugs, with Ukoniq being an oral therapy and Glofitamab being an intravenous therapy.

Difference between Ukoniq and Columvi

Metric	Ukoniq (umbralisib)	Columvi (glofitamab-gxbm)
Generic name	Umbralisib	Glofitamab-gxbm
Indications	Marginal zone lymphoma (MZL), Follicular lymphoma (FL)	Currently under investigation, potential use in B-cell lymphoma
Mechanism of action	PI3K delta inhibitor	Bi-specific monoclonal antibody targeting CD20 on B-cells and CD3 on T-cells
Brand names	Ukoniq	Columvi
Administrative route	Oral	Intravenous
Side effects	Increased risk of infection, diarrhea, fatigue, nausea, and others	Not fully characterized, but may include cytokine release syndrome, infusion-related reactions, and others
Contraindications	None known beyond hypersensitivity to umbralisib	Not fully established, likely similar to other monoclonal antibodies
Drug class	Small molecule inhibitor	Monoclonal antibody
Manufacturer	TG Therapeutics	Genentech, a member of the Roche Group

Efficacy

Ukoniq (Umbralisib) Efficacy in Treating Lymphoma

Ukoniq (umbralisib) is a medication that has been approved for the treatment of certain types of lymphoma. Specifically, it has been indicated for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for adult patients with relapsed or refractory follicular lymphoma (FL) after at least three prior lines of systemic therapy. Umbralisib is a kinase inhibitor that works by targeting both the PI3K delta and the CK1-epsilon, which are enzymes that contribute to the growth and survival of malignant B-cells.

The efficacy of Ukoniq in lymphoma was evaluated in a multicenter, open-label, single-arm trial. In this trial, the overall response rate (ORR) was used as a primary measure of efficacy. For patients with MZL, the ORR was reported to be approximately 49%, with a complete response (CR) rate of 16%. For patients with FL, the ORR was found to be around 43%, with a CR rate of 3%. These results demonstrate that Ukoniq can induce a significant proportion of responses in patients with these relapsed or refractory conditions.

Columvi (Glofitamab-gxbm) Efficacy in Treating Lymphoma

Columvi (glofitamab-gxbm) is an investigational bispecific monoclonal antibody designed for the treatment of lymphoma. While not yet approved, glofitamab-gxbm has shown promise in clinical trials for non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Glofitamab-gxbm targets both CD20 on B-cells and CD3 on T-cells, thereby bringing these cells into close proximity and promoting T-cell-mediated killing of the B-cell lymphoma.

In clinical studies, glofitamab-gxbm has been evaluated for its efficacy in patients with relapsed or refractory B-cell lymphomas. Preliminary data from these studies have suggested encouraging response rates, with some patients achieving complete remission. However, as an investigational drug, the full profile of glofitamab-gxbm's efficacy and safety is still under investigation, and more data from ongoing clinical trials are needed to fully establish its therapeutic potential in lymphoma.

Regulatory Agency Approvals

Ukoniq

Food and Drug Administration (FDA), USA

Columvi

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Ukoniq or Columvi today

If Ukoniq or Columvi are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Ukoniq

Buy Columvi

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: